Theravance Biopharma (TBPH) Phase 2b Dose-Finding Induction Study of Izencitinib Did Not Meet Primary Endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. SMCI
6. GOOGL
7. RTX
8. COF
9. TSLA
10. META

Go back to Theravance Biopharma (TBPH) Phase 2b Dose-Finding Induction Study of Izencitinib Did Not Meet Primary Endpoint

Theravance Biopharma (TBPH) PT Lowered to $18 at Needham & Company

August 24, 2021 6:24 AM EDT

Needham & Company analyst Joseph Stringer lowered the price target on Theravance Biopharma (NASDAQ: TBPH) to $18.00 (from $32.00) while maintaining a Buy rating.

The analyst commented, "TBPH announced yesterday the izencitinib Ph2b RHEA trial in Ulcerative Colitis (UC) failed to demonstrate efficacy vs... More

Theravance Biopharma (TBPH) falls 21% as trading resumes after a trial missed the primary endpoint

August 23, 2021 4:37 PM EDT

Theravance Biopharma (NASDAQ: TBPH) falls 21% as trading resumes after a trial missed the primary endpoint.

... More

Theravance Biopharma (TBPH) to resume trading at 4:35PM ET after a trial did not meet the primary endpoint

August 23, 2021 4:10 PM EDT

Theravance Biopharma (NASDAQ: TBPH) to resume trading at 4:35PM ET after a trial did not meet the primary endpoint.

... More